Get a FirstLook at Lung Cancer

FirstLook Lung is an accessible blood test to aid in early lung cancer detection.

Discover the 4 steps to the FirstLook liquid biopsy blood test.

Detecting lung cancer early saves lives.1

FirstLook Lung offers a convenient, accessible, personalized approach to enhance lung cancer screening.

Breakthrough Technology

FirstLook uses a unique fragmentomics technology that analyzes DNA fragment patterns to help screen for lung cancer.2,5

Easily Accessible

FirstLook makes lung cancer screening accessible to all eligible adults by keeping the process simple.

Simple & Efficient

The FirstLook blood test can be incorporated into routine appointments, making it easier for more adults to start lung cancer screening.

15.1 million Americans are at an elevated risk for lung cancer and are screen-eligible, but most are not getting the necessary screening to detect it early before signs or symptoms appear.3

Whether it’s due to inaccessible screening methods or lack of awareness, the vast majority of eligible adults aren’t getting the nationally recommended low-dose CT (LDCT) screening.4

The FirstLook test has a negative predictive value* of 99.8%.5

The FirstLook blood test offers a convenient and accessible way to enhance lung cancer screening and early lung cancer detection.

*The negative predictive value represents the percentage of individuals with a Not Elevated result who do not have low-dose CT detectable lung cancer. The clinical validity of FirstLook Lung was established by a prospective, case-controlled study in a population of screen-eligible patients.2

Find additional resources and support from these trusted partners:

Lungevity Transforming Lung Cancer logo
GO2 FOR LUNG CANCER logo

Lung cancer screening is only the start.

DELFI Diagnostics is committed to bringing high-performing liquid biopsy blood tests to aid cancer detection that are accessible to all.

DELFI logo

Learn more about DELFI and our mission.

Healthcare professionalsHealthcare professionals

Want to stay updated
on FirstLook?

Thank you for signing up with us.

If you are a healthcare professional, sign up to learn more.

You have been added to our mailing list and will begin receiving information about FirstLook soon.

    Required*

    By providing your information and selecting the Sign Up button, you agree to receive information on FirstLook.

    Click here to view our privacy policy.

    Image of Healthcare Provider

    References

    1. National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 365(5), 395-409. 2. Mazzone PJ, et al. Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection. Cancer Discov. 2024 Jun 3. doi: 10.1158/2159-8290.CD-24-0519. Epub ahead of print. PMID: 38829053. 3. Meza, R., Jeon, J., Toumazis, I., Ten Haaf, K., Cao, P., Bastani, M., Han, S. S., Blom, E. F., Jonas, D. E., Feuer, E. J., Plevritis, S. K., de Koning, H. J., & Kong, C. Y. (2021). Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA, 325(10), 988–997. 4. Wang GX, Baggett TP, Pandharipande PV, Park ER, Percac-Lima S, Shepard JO, Fintelmann FJ, Flores EJ. Barriers to Lung Cancer Screening Engagement from the Patient and Provider Perspective. (2019). Radiology, 290(2), 278-287.  5. Unpublished data on file.

    X